Trial Profile
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Doxorubicin
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DSMM XIV
- 11 Jul 2023 This trial has been completed (End Date: 26 May 2023), according to European Clinical Trials Database record.
- 26 Apr 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 26 Apr 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.